MeiraGTx vs Regenxbio
MGTX and RGNX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How MGTX and RGNX compare
MeiraGTx is the larger company, worth 1.7 times as much as Regenxbio ($813M against $478M).
MeiraGTx grew revenue faster over the last twelve months (948% versus 12.0% for Regenxbio).
MeiraGTx keeps more of each dollar of sales as profit, with a net margin of 19.9% compared with −113% at Regenxbio.
MeiraGTx scores higher on the StockData Score (13 against 4 for Regenxbio), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | MGTX | RGNX |
|---|---|---|
| Size and price | ||
| Market cap | $813M | $478M |
| Share price | $8.46 | $7.24 |
| Change, 1 year | 3.3% | −37.1% |
| Change, 5 years | −52.9% | −76.6% |
| Beta (5Y) | 2.14 | 2.63 |
| Employees | 403 | 371 |
| StockData Score | ||
| Total score | 13 (better) | 4 |
| Valuation score | 4 (better) | 0 |
| Growth score | 2 | 2 |
| Performance score | 4 (better) | 1 |
| Health score | 3 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 11.9× | – |
| P/S | 2.0× (better) | 2.7× |
| P/B | – | 6.7× |
| EV/EBITDA | 3.9× | – |
| P/FCF | 77.6× | – |
| FCF yield | 1.3% (better) | −52.2% |
| Fair value | $24.37 | – |
| Margin of safety | 65.3% | – |
| Growth | ||
| Revenue growth (TTM) | 948% (better) | 12.0% |
| Revenue growth, 5Y average | 39.2% (better) | 2.0% |
| Profitability | ||
| Operating margin | 46.3% (better) | −94.1% |
| Net margin | 19.9% (better) | −113% |
| FCF margin | 2.6% (better) | −143% |
| Return on equity | 2668% (better) | −138% |
| Return on invested capital | 344% | – |
| Financial health | ||
| Net debt / EBITDA | −0.22 | – |
| Interest coverage | 14.7× (better) | −3.9× |
| Current ratio | 3.76 (better) | 2.86 |
| Altman Z-score | 3.24 (better) | −3.88 |
| Piotroski F-score | 4 | 4 |
| Dividends and buybacks | ||
| Buyback yield | −16.4% | – |
| Shareholder yield | −16.4% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 82.5% | 64.2% |
| Held by insiders | 35.2% | 7.6% |
| Insider net buying, 12 months | −$4.7M | $9.6K (better) |
| Short interest, % of float | 10.7% | 16.7% |
Go deeper
- MGTX stock overview
- MGTX income statement
- MGTX valuation and score
- RGNX stock overview
- RGNX income statement
- RGNX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.